Preventive bundles to reduce catheter-associated bloodstream infections in neonatal intensive care

Präventivbündel zur Reduzierung katheterassoziierter Blutbahninfektionen in der neonatalen Intensivmedizin

Abstract

This systematic survey includes a total of 27 studies published between 2002 and 2016 on the benefit of preventive bundles for the prevention of central-line associated bloodstream infections (CLABSI) in neonatal intensive care. These studies are mainly cohort studies or studies analyzing an interrupted time series before and after intervention. The studies showed heterogeneity in terms of endpoint definitions (CLABSI), details of the implemented measures, and evidence of a publication bias favoring the use of preventive bundles. The cumulative analysis showed a statistically and clinically significant benefit of preventive bundles to avoid CLABSI in neonatal intensive care.

Keywords: preterm infants, neonatal intensive care, central-line associated bloodstream infection, preventive bundle

Zusammenfassung

In einer systematischen Übersicht zu neonatologischen Intensivpatienten mit zentralem Venenkatheter wurden die Ergebnisse von insgesamt 27 Studien ausgewertet, die den Nutzen von Präventionsbündeln zur Vermeidung von katheterassozierten Blutstrominfektionen (CLABSI) untersucht haben. Die eingeschlossenen Studien wurden zwischen 2002 und 2016 publiziert. Die meisten Studien waren Kohortenstudien oder unterbrochene Zeitserien vor und nach Einführung von Präventionsbündeln. Entsprechend heterogen sind die Definitionen der Endpunkte und die unterschiedlichen präventiven Maßnahmen; zudem gab es Hinweise auf einen Publikationsbias zugunsten von Präventionsbündeln. Trotz dieser methodischen Limitationen zeigen die analysierten Studien einen signifikanten und klinisch sehr relevanten Nutzen von Präventionsbündeln in der neonatologischen Intensivpflege.

Schlüsselwörter: Frühgeborene, neonatologische Intensivtherapie, ZVK-assoziierte Blutst AMAZINFektion, Präventionsbündel

Background

Preterm infants and neonates in intensive care bear a high risk for nosocomial infections (NI) [1]. Level 1 and level 2 highest-care NICUs are among those risk areas where selected NI are monitored prospectively, in addition to monitoring of invasive pathogens and their antibiotic resistance profiles [2]. The findings serve to improve patient safety and quality of treatment by preventing NIs, preventing infection by multiresistant pathogens, and optimizing the use of antibiotics [3]. Local findings of the German NEO-KISS monitoring can be checked against anonymized reference data [4], [5], [6], [7], [8]. For example, there is a positive effect of prospective monitoring on the reduction of central-line associated bloodstream infections (CLABSI) [9].

The use of central (CVC) and peripheral venous catheters (PVC) has been identified as an independent risk factor for late-onset sepsis (LOS) in NEO-KISS participants [7]. NICUs mostly use umbilical vein catheters (UVC) and peripherally inserted central venous catheters (PICC) as central lines. Analysis and evaluation of NEO-KISS data yield important information on quantity, etiology, and pathogen range of CLABSI [10], [11]. Between January 2012 and December 2016, the median CLABSI rate (incidents per 1,000 CVC utilization days) in preterm infants was 8.62 at a birth weight (BW) of 499 g, 5.29 at BW 500 to 999 g, 5.29, and 2.35 at BW 1,000 to 1,499 g. Thus,
NICUs show a significantly higher CLABSI rate than pediatric ICUs [12]. Fortunately, the CLABSI rate of preterm infants with a birth weight below 1,500 g (very low birth weight, VLBW) has decreased continuously for years now. Between 2007 and 2011, PVC-associated sepsis rates were nearly constant between 6.7 and 7.5 per 1,000 PVC utilization days [4], but most recently, between January 2012 and December 2016, the median rate per 1,000 PVC utilization days was 3.44 in ELBW preterm infants (birth weight between 500 and 999 g) and 2.18 in VLBW preterm infants (birth weight 1,000 to 1,499 g).

In 2007, the German Commission for Hospital Hygiene and Infection Prevention (KRINKO) published a recommendation for the prevention of nosocomial infections in NICU patients [13], comprising explicit recommendations for the prevention of infections associated with central lines. An update has been published recently [14] in order to support specialist NICU teams in reviewing and sustainably implementing their local standard of CLABSI prevention [15].

To merge single measures e.g. from national guidelines into an individual bundle for each hospital may lead to a significant improvement in treatment quality in the long term [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38].

The aim of this systematic investigation was to evaluate the available studies on the use of preventive bundles for the prevention of CLABSI in NICUs. This should lead to a better basic understanding of the benefits of preventive bundles in this special context and point to the characteristics of this patient population.

**Methods**

We searched papers in PubMed (last search Oct. 1, 2016; key words "central venous line, neonatal intensive care, prevention, preventive bundle, central line-associated bloodstream infection") and included secondary citations found in these articles and surveys to find clinical studies which were published according to peer-review procedures in Medline-listed scientific journals between 2002 and 2016. Eligible studies contained precise information on the most important aspects of infection prevention when inserting or handling central venous lines in neonatal ICU patients. Moreover, they had to present the method of diagnosing CLABSI, endpoint definitions and the effect of the preventive strategy, e.g., on the CLABSI rate in %, CLABSI incidences per 1,000 hospitalization days, or the CLABSI incidence rate per 1,000 treatment days. As randomized controlled studies have been performed very rarely in this patient population, we also included studies which used other infectiological-epidemiological methods to compare patient populations with similar basic pre- and postinterventional characteristics (implementation of preventive bundle) [39].

The most important information was entered into a structured table of findings. Where applicable, the presented survey pointed out methodological limitations of the studies, keeping in mind the basic limitations of non-prospectively randomized controlled studies.

Eight studies disclosed the pre- and postinterventional CLABSI incidence rate (incidents per 100 patients), 7 studies contained evidence for an incident rate (incidents per 1,000 treatment days), and in both groups, the original publication provided information on the number of patients, number of incidents, or number of treatment days for central lines. We merged the data of this specific selection from the the total number of studies we found into an outlined meta-analysis. We used StatsDirect version 3.0.183 (Nov. 1, 2016) for meta-analysis and for calculating the combined relative risk, with a corresponding 95% confidence interval. Applying the so-called fixed effects model in combination with Cochran’s Q test, the null hypothesis “there is heterogeneity between the studies” was permissible. Forest plots were used for data presentation. Additionally, the findings were analyzed by means of a funnel plot and the corresponding Egger’s Test for Symmetry to show a possible publication bias.

**Results**

**Number and methodology of the enclosed studies**

A total of 27 studies were included in this analysis; see survey in Table 1 and Table 2. The design of the included studies was heterogeneous. There were monocenter retrospective surveillance studies [27], [28], [30], [33], [40], [41], [42], an experimental study [26] and prospective cohort studies [34], [35], [38], [43], [44], [45], [46], [47], [48]. Moreover, we analyzed 10 multicenter studies performed by cooperative surveillance networks [24], [25], [29], [36], [37], [49], [50], [51], [52], [53]. The multicenter studies comprised findings from 6 [53] to 100 NICUs [24] per study. To the authors’ knowledge, no prospectively randomized controlled studies were published on the use of preventive bundles in neonatal ICU patients up to September 2017.

**Definition of incidents**

Most studies [24], [25], [27], [29], [30], [33], [35], [36], [38], [42], [43], [45], [46], [50], [52] use the criteria of the Centers for Disease Control and Prevention (CDC) [54] to define CLABSI. Attention should be paid to the fact that in 2008, there was a change in the CDC’s definition of CLABSI caused by CoNS or other potential blood culture contaminants. From 2008 onwards, two independent blood cultures were demanded for verifying a BSI in every case [54]. When the respective study was not completed in 2008 or when investigation of a required control group took place before 2008, the problem arose of two different definitions during the time of the same study [26], [27], [29], [35], [42], [52]. In 3 studies, the data were corrected retrospectively using the new
Table 1: Included studies, setting, study type and surveillance period

| Author and year | Setting                                                                 | Study type                                                                 | Surveillance period                                                                 |
|-----------------|-------------------------------------------------------------------------|-----------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| McMullan et al. 2016 [40] | NICU. Royal Prince Alfred Hospital. Sydney (Australia) University Hospital | retrospective cohort study, prospectively documented data                   | baseline: Jan. 2012 – Dec. 2012 intervention: Aug. 2013 – July 2014                |
| Aly et al. 2005 [41]   | NICU. George Washington University Hospital. Washington DC (USA)       | retrospective cohort study                                                  | Jan. 1998 – Dec. 2000 Jan. 2001 – Dec. 2003                                      |
| Bizzarro et al. 2010 [26] | 54 bed NICU Yale-New Haven Children’s Hospital. Connecticut (USA)     | cohort study to improve treatment quality                                   | baseline: July 2005 – June 2007 postintervention: Jan. 2008 – March 2009          |
| Bowen et al. 2017 [49] | multicenter QI; 8 NICUs from New South Wales and Australian Capital Territory (Australia) | prospective cohort study                                                   | Jan. 2013 – Dec. 2014; comparing with data from 2012                             |
| Chandonnet et al. 2013 [43] | Boston Children’s Hospital in Boston. Massachusetts (USA) 24 bed NICU | prospective cohort study                                                    | pre-implementation phase: March–Sept. 2011 → project concept implementation phase: Oct. 2011 → introduction of guidelines in NICUs postintervention: Nov. 2011 – July 2012 |
| Curry et al. 2009 [27] | Arkansas Children’s Hospital. Arkansas (USA) 85 bed NICU             | retrospective cohort study                                                  | 2005 to 2008                                                                     |
| Dumpa et al. 2016 [30] | Children’s Hospital (Saint Peter’s University Hospital) New Jersey (USA) 54 bed NICU | retrospective cohort study                                                  | intervention period: April–Dec. 2011 postintervention period: Jan. 2012 – Aug. 2013 |
| Fisher et al. 2013 [50] | Participants of PQCNC-CA-BSI-project 13 NICU in North Carolina (USA) | prospective cohort study                                                   | baseline: Jan 2008 – Sept 2009 intervention: Oct 2009 – June 2010 follow-up: 3 months after intervention and 12 months after intervention |
| Golombek et al. 2002 [28] | University Medical Center at Stony Brook; New York (USA)             | retrospective cohort study, prospectively documented data                   | baseline: 1993–1995 intervention: Feb 1998 – May 1999                           |
| Health Research & Educational Trust (HRET) et al. 2011 [24] | 100 NICU from 9 US States the hospitals had an average of 26 NICU beds and 13 neonatal intermediate care beds | prospective cohort study                                                   | baseline: Oct.–Dec. 2011 intervention: Jan.–Aug. 2012                          |
| Holzmann-Pazgal et al. 2012 [35] | Children’s Memorial Hermann Hospital Houston. Texas (USA) NICU 118 beds | prospective cohort study                                                   | pre-intervention period (baseline): Dec. 2006 – Feb. 2008 postintervention period (intervention): March 2008 – Aug. 2010 |
| Kaplan et al. 2011 [51] | Ohio Perinatal Quality Collaborative (OPQC) in 24 NICUs in Ohio       | analysis of interrupted time series                                         | baseline: April 2006 – Aug. 2008 intervention: Sept. 2008 – Dec. 2009            |
| Neill et al. 2016 [44] | Duke University Medical Center. University Hospital in North Carolina (USA) | prospective cohort study                                                   | pre-intervention: 2005–2007 intervention (phase 1): 2007–2009 intervention (phase 2): 2010–2013 |
| Piazza et al. 2016 [36] | 17 hospitals of the CHND (Children’s Hospitals Neonatal Database) Initiative all: >25 NICU beds | prospective cohort study                                                   | baseline: Jan.–Dec. 2011 intervention: Jan.–Dec. 2012                           |
| Rallis et al. 2016 [45] | Aristotle University of Thessaloniki, Papageorgeous General Hospital (Greece) NICU. 26 beds | prospective cohort study                                                   | pre-intervention period: Jan.–Sept. 2012 intervention period: Oct.–Dec. 2012 postintervention period: Jan.–Sept. 2013 |
Table 1: Included studies, setting, study type and surveillance period

| Author and year | Setting | Study type | Surveillance period |
|-----------------|---------|------------|---------------------|
| Sannoh et al. 2010 [46] | Maria Fareri Children’s Hospital, New York (USA) 50 beds (Children’s Hospital, NICU) | prospective interventional study | pre-intervention period: June 2005 – Feb. 2006 postintervention period: March 2006 – March 2007 |
| Schulman et al. 2011 [52] | 18 regional perinatal centers of the State New York (USA) | prospective cohort study | pre-intervention period: Jan.–Dec. 2007 postintervention period: March–Dec. 2009 |
| Shepherd et al. 2015 [29] | Nationwide Children’s Hospital Columbus, Ohio (USA) | continuous prospective surveillance | 2003 to 2013 interventions: 2007–2011 |
| Steiner et al. 2015 [34] | NICU at the University Hospital in Vienna (Austria) | prospective cohort study | pre-intervention period: 2010 postintervention period: 2011–2012 |
| Ting et al. 2013 [42] | BC Women’s Hospital and Health Centre, Vancouver (British Columbia, Canada) NICU: 60 beds | 1. retrospective surveillance study 2. interventional study period 1: Aug. 2007 – June 2008 period 2: July 2008 – May 2009 period 3: June 2009 – April 2010 period 4: May 2010 – March 2011 | |
| Wirthschafter et al. 2010 [25] | OI Collaborative in California (USA) 13 NICUs all NICUs: between 23 and 84 beds | prospective interventional cohort study | baseline: Jan.–Aug. 2006 intervention: Sept. 2006 – June 2007 follow-up: July–Dec. 2007 |
| Salm et al. 2016 [37] | 32 NICUs in Germany by NEO-KISS | multicenter prospective surveillance module | baseline: July 2007 – June 2009 intervention period: July 2009 – June 2010 postintervention period: July 2010 – June 2011 |
| Cooley et al. 2009 [47] | Northside Hospital in Atlanta; Georgia. (USA) NICU 125 beds | prospective cohort study | 2001 – June 2008 |
| Kilbride et al. 2003 [53] | USA: 6 NICUs of the Vermont Oxford Network (VON) | prospective cohort study | 1997–2000 |
| Zhou et al. 2015 [38] | Children’s Hospital of Fudan University, Shanghai (China) NICU with 30 beds (since June 2008: 50 beds) note: CVCs were only introduced in this hospital in 2004 and official part of a NICU routine procedure since March 2007 | prospective cohort study | baseline phase (phase 1): Jan.–Dec. 2008 intervention phase (phase 2): Jan.–Dec. 2009 follow-up (phase 3): Jan.–Dec. 2010 |
| Wilder et al. 2016 [48] | 36 bed NICU in the southwest of the United States | prospective cohort study | 2011–2014 |
| Kime et al. 2011 [33] | Covenant Hospital in Saginaw; Michigan (USA) 55 bed NICU | prospective cohort study | baseline: May–Oct. 2009 postintervention: July–Sept. 2010 |

Definition [26], [35], [52]. One other study kept the previous definition [42]. Two studies [34], [37] used the definitions of the German NEO KISS Module [4]. Two studies [47], [48] did not describe the definition of incidents in detail.

The primarily documented incidents of some studies were reviewed by independent infectiology/hygiene specialists [30], [33]. Golombek et al. [28] registered blood-culture-negative CLABSIs in the case of a clinical worsening with suspected infection and subsequently 7 days of antibiotic treatment, beginning 24 hrs after PICC insertion or within 24 hrs after PICC removal. Finally, there are studies in which the endpoint definitions do not exactly match the ones of CDC or NEO-KISS [28], [40], [41], [44], [49], [51], [53].
| Author and year | Number of patients/patient characteristics | Definition of CLABSI | Outcome rate CLABSI/1,000 days in use |
|-----------------|------------------------------------------|---------------------|-------------------------------------|
| McMullan et al. 2016 [40] | baseline: n=214 / median GA (gestational age) 32 weeks, median BW (birth weight) 1,660 g / Chorioamnionitis 30% intervention: n=162 / median GA 31 weeks, median BW 1,644 g / Chorioamnionitis 38% | **Own definition:** CLABSI: confirmed BSI and CVC in use for more than 48 hrs before signs and symptoms of infection occurred. Confirmed BSI: growth of pathogen in blood culture and antibiotics therapy. In case of potential contaminants: monoculture of pathogen plus laboratory signs of infection or repeated proof in blood culture. | This study also included UVCs. baseline 8.5 after intervention 2.3 relative risk: 0.3 (CI 95%: 0.1–0.86) |
| Aly et al. 2005 [41] | baseline: n=169 intervention: n=367 significant differences in both groups: median GA. median BW; share of VLBW; median hospitalization | **Own definition:** positive blood culture with contaminants: proof by second positive blood culture. not defined as BSI when antibiotics <72 hrs | No information on inclusion of UVCs. baseline 15.17 intervention 2.1 odds ratio pre- vs. postintervention: 4.15 (95% CI 2.1–8.3) |
| Bizzarro et al. 2010 [26] | baseline 417 neonates (522 percutaneous CVCs and 49 surgically implanted CVCs) intervention 169 neonates (171 percutaneous CVCs and 33 surgically implanted CVCs) significant differences in groups: ELBW → baseline: 29.5%; intervention: 43.4% duration of ventilation. intubation (median) → baseline: 4 days; intervention: 8 days | CDC definitions before 2008; used further on after the change in 2008. But: additional separate analysis with definitions after 2008. Adjustment of results regarding differences in BW between both populations. | no UVC. CDC definition before 2008: baseline: 8.40 intervention: 1.28 RR: 0.19 (CI 95%: 0.08–0.45) CDC definition after 2008: baseline: 7.01 intervention: 1.28 RR: 0.26 (CI 95%: 0.11–0.64) |
| Bowen et al. 2017 [49] | 1,075 neonates (<29 week of pregnancy) | **Own definition:** BSI: 1. defined pathogen in blood culture or 2. growth of possible contaminant (e.g. CoNS) in blood + treatment with antibiotic ≥96 hrs (or death <96 hrs) + growth of same organism in repeated blood culture or ≥1 pathological lab marker or clinical symptoms of systemic infection a positive blood culture was encoded as contamination when: the organism was a potential skin contaminant and the patient was treated with antibiotics <96 hrs individual assessment by interdisciplinary team. CA-BSI: BSI + PICC / navel vein catheter in use or BSI within 48 hrs after removal except there was a different source of BSI. | This study also included UVCs. baseline 9.9 ± 4.3 intervention (2013) 8.1 ± 3.9 intervention (2014) 5.4 ± 1.7 |
| Author and year | Number of patients/patient characteristics | Definition of CLABSI | Outcome rate CLABSI/1,000 days in use |
|-----------------|------------------------------------------|----------------------|-------------------------------------|
| Chandonnet et al. 2013 [43] | No information on number of patients. CVC days: - baseline: 1,933 - intervention: 392 - postintervention: 2,411 patient days: - baseline: 4,332 - intervention: 649 - postintervention: 5,570 application rates: - baseline: 0.45 - intervention: 0.60 - postintervention: 0.43 | CDC criteria of 2008 | No information on inclusion of UVCs. baseline: 2.6 intervention: 2.6 postintervention: 0.8 |
| Curry et al. 2009 [27] | 2007: 470 patients with CVC 2008: 263 patients with CVC | CDC criteria after 2008 | UVC not included. PICC 2005: 3.1 2007: 1.1 Broviac catheter 2005: 9.3 2007: 3.3 overall 2005: 4.9 2007: 2.1 |
| Dumpa et al. 2016 [30] | Interventional and postinterventional groups were comparable regarding: BW, GA, sex., premature rupture of membranes, maternal fever, premature labor, mode of delivery, days of ventilation, duration of hospitalization CVC days: pre-intervention: 2009: 1,934; 2010: 2,342 intervention: 1,375 postintervention: 2,373 | CDC criteria after 2008 | This study also included UVCs. pre-intervention 2009: 2.1 2010: 1.3 intervention: 4.4 postintervention: 0 |
| Fisher et al. 2013 [50] | no information | CDC criteria after 2008 | No information on inclusion of UVCs. baseline: 3.94 intervention: Jan. 2010: 1.16 follow-up: July 2010 – June 2011: 1.16 July 2011: 0.67 |
| Author and year | Number of patients/patient characteristics | Definition of CLABSI | Outcome rate CLABSI/1,000 days in use |
|-----------------|--------------------------------------------|---------------------|-------------------------------------|
| Golombek et al. 2002 [28] | baseline: 89 / (average) intervention: 47 / (average) BW and weight at placement are significantly lower in the interventional group | **Own definition:** CLABSI: clinical worsening and positive blood culture and use of antibiotics when PICC was indwelling for min. 24 hrs or when PICC was removed within the last 24 hrs **CLABSI, bloodculture negative:** clinical worsening and 7 days antibiotics therapy or: start 24 hrs after PICC placement or: within 24 hrs after PICC removal | **UVC not included:** baseline: 15.8 intervention: 5.1 |
| Health Research & Educational Trust (HRET) et al. 2011 [24] | overall CVC days baseline: 13,215 intervention: Jan.: 15,187; Feb.: 15,655; March: 17,728; April: 18,257; May: 19,558; June: 17,296; July: 16,318; Aug.: 11,690 | CDC criteria after 2008 | **This study also included UVCs:** baseline: 2.04 intervention: 2.04 Feb.: 0.70; March: 1.35; April: 0.99; May: 1.13; June: 1.16; July: 1.10; Aug.: 0.86 |
| Holzmann-Pazgal et al. 2012 [35] | no information | CDC criteria before 2008, later corrected basing on the changed definitions of 2008 | **This study also included UVCs:** baseline: 12.9 → 11.6 (adjusted after change of definition) intervention: 4.0 pre-intervention: (CVC team) GG 751–1,000 g: 9.7 postintervention: GG 751–1,000 g: 5.3 → no significant change of CLABSI rate significant difference in all other weight groups. |
| Kaplan et al. 2011 [51] | intervention: information from 125,150 patient care days of which 42,612 days with indwelling CVC | **Own definition:** Nosocomial infection definition (Vermont Oxford Network) 1. positive blood or liquor culture ≥72 hrs after birth or 2. positive (CoNS) blood or liquor culture ≥72 hrs after birth and clinical signs of infection and antibiotics therapy for at least 5 days **CLABSI: no other focus. CVC in use or removed less than 48 hrs ago.** | **Prevalence of late-onset sepsis** baseline: 18.2% intervention: 14.0% during intervention 69% of LOS were CLABSI (no baseline data for this share) |
| Author and year | Number of patients/ patient characteristics | Definition of CLABSI | Outcome rate CLABSI/ 1,000 days in use |
|----------------|---------------------------------------------|----------------------|---------------------------------------|
| Neill et al. 2016 [44] | 2005 to 2013: 6,790 infants were admitted to NICUs 2005–2007: 2,186 patients 2008–2010: 2,311 patients 2011–2013: 2,293 patients | **Own definition:** BSI: positive blood culture min. 48 hrs after birth If CoNS were found in a positive blood cultures this was held to be an infection if:  - 2 positive blood cultures within 4 days  - 3 positive blood cultures within 7 days  - 4 positive blood cultures within 10 days | in this study: BSI/1,000 patient days pre-intervention: 5.62 intervention (2009): 2.44 intervention (2010): 0.27 BSI/ 2013: 0.25 |
| Piazza et al. 2016 [36] | baseline: 116,987 CVC days in use intervention: 119,003 CVC days in use | CDC criteria after 2008 | No information on inclusion of UVCs. baseline: 1.33 intervention: 1.08 CLABSI rate dropped by 19.3% |
| Rallis et al. 2016 [45] | pre-intervention: 94 postintervention: 59 | CDC criteria after 2008 | This study also included UVCs. pre-intervention: 12.0 postintervention: 3.4 |
| Sannoh et al. 2010 [46] | pre-intervention period: 163 postintervention period: 210 CVC days: pre-intervention period → 2,926; postintervention period → 3,229 | CDC criteria before 2008 | This study also included UACs and UVCs pre-intervention period: UAC.UVC: 15 PICC: 23 postintervention period: UAC. UVC: 5 PICC: 12 UAC.UVC odds ratio: 0.47 (CI 95%: 0.17–0.91) PICC odds ratio: 0.33 (CI 95%: 0.12–0.91) |
| Schulman et al. 2011 [52] | pre-intervention period: CVC days: 61,096; patient days: 237,996; CVC application rate: 0.26 postintervention period: CVC days: 55,137; patient days: 206,846; CVC application rate: 0.27 | Initially CDC criteria before 2008, later there was a retrospective review and adaptation of data according to the definition after 2008. | No information on inclusion of UVCs. after 2008 with adjusted data: pre-intervention period: 3.5 postintervention period: 2.1 relative risk 0.6 (95%CI: 0.48–0.75) |
| Shepherd et al. 2015 [29] | CVC days: 2003: 8,888; 2007: 13,580; 2009: 13,479; 2011: 13,226; 2013: 11,059 patient days: 2003: 30,449; 2007: 43,947; 2009: 47,679; 2011: 50,002; 2013: 54,923 | CDC criteria after 2008 | No information on inclusion of UVCs. Jan. 2007: 6.0 May 2007: 1.43 June 2008: 0.68 2013: 0.54 (significant reduction since May 2007) |
| Author and year | Number of patients/patient characteristics | Definition of CLABSI | Outcome rate CLABSI/1,000 days in use |
|----------------|--------------------------------------------|---------------------|-------------------------------------|
| Steiner et al. 2015 [34] | patients during whole study: 526 VLBW 2010: patients: 168 2011: patients: 161 2012: patients: 197 | NEO-KISS definition | UVC not included. 2010: 13.9 2011: 9.5 2012: 4.7 |
| Ting et al. 2013 [42] | number of CVC days: period 1: 3,958; period 2: 4,004; period 3: 4,527; period 4: 4,068 | CDC criteria before 2008 | This study also included UVCs. period 1: 7.9 period 2: 3.3 period 3: 2.6 period 4: 2.2 |
| Wirschafter et al. 2010 [25] | overall patient days: 2006: 196,005 (CVC days: 59,182) 2007: 203,670 (CVC days: 73,077) | CDC criteria before 2008 | This study also included UVCs. overall cohort result: baseline: 4.32 follow-up: 3.22 reduction by 25% |
| Salm et al. 2016 [37] | 6,222 patients; 231,868 patient days (overall) baseline: 113,867 intervention period: 62,488 postintervention period: 55,513 | NEO-KISS definition | PVC-associated incidences baseline: 3.04 interventio speriod: 2.58 (no significance) postintervention period: 2.29 (→ p=0.005) postintervention period relatives risk 0.75 (CI 95%: 0.61–0.92) CVC-associated incidences baseline: 2.63 intervention period: 2.19 (no significance) postintervention period: 1.98 (p=0.009) postintervention period relative risk 0.75 (CI 95%: 0.60–0.93) |
| Cooley et al. 2009 [47] | no information | CDC Criteria before 2008 | UVC not included. 2000: 6.3; 2001: 6.2; 2002: 5.6; 2003: 6.3; 2004: 4.2; 2005: 3.8; 2006: 2.2; 2007: 2.8; 2008 (Oct. 2007 – June 2008): 1.3 |
| Author and year          | Number of patients/patient characteristics | Definition of CLABSI                                                                 | Outcome rate CLABSI/1,000 days in use |
|-------------------------|--------------------------------------------|--------------------------------------------------------------------------------------|---------------------------------------|
| Kilbride et al. 2003 [53]| no information                             | Own definition: at suspected infection: 2 separate blood cultures. minimum volume 1 ml | the median incidence of CoNS bacteremia was chosen as outcome 1997: 24.6% July–Dec. 2000: 16.4% relative risk 0.67 (95%CI: 0.51–0.87) |
| Zhou et al. 2015 [38]   | 171 patients during study phases with 10,299 patient days phase 1: 29 phase 2: 51 phase 3: 91 this study included a share of infants of >2,500 g phase 2 and 3: phase 2: <2,500g: 88% phase 3: <2,500g: 95% CVC days phase 1: 480; phase 2: 1,177; phase 3: 2,287 CVC application rate phase 1: 0.24; phase 2: 0.39; phase 3: 0.42 → statistically significant increase of CVC application rate | CDC criteria after 2008 | This study also included UVCs. phase 1: 16.7 phase 2: 7.6 phase 3: 5.2 relative risk phase 3 0.31 (CI 95%: 0.13–0.77) |
| Wilder et al. 2016 [48] | CVC days/year: 2011: 2,308; 2012: 3,313; 2013: 3,679; 2014: 3,880 | no information, most likely CDC definitions | no information on inclusion of UVC, information only refers to PICCs 2011: 3.9 2012: 1.5 2013: 1.4 2014: 0.26 |
| Kime et al. 2011 [33]   | baseline: 71 infants CVC days: 1–86 days (median: 17 days) postintervention: 29 infants CVC days: 1–88 days (median: 12 days) overall days in use (PICC+Browiac): 2009: 1,727; 2010: 1,512 | CDC criteria after 2008 | no information on inclusion of UVC baseline: 15.6 postintervention: 0 → clinical significance. but no statistical significance. |

Abbreviations: please refer to list of abbreviations
Blood culture diagnostics

The only detailed description of the blood culture sampling procedure is reported in the paper by Kilbride et al. [53]; in the case of a suspected infection, two peripheral venous blood cultures with a minimum volume of 1 ml were drawn. Most studies contain information on the required number of blood cultures [24], [25], [26], [27], [28], [29], [30], [33], [34], [35], [36], [37], [38], [40], [41], [42], [43], [44], [45], [46], [49], [50], [51], [52], [53], but do not comment on the minimum volume of blood per culture bottle.

Definition of prevention goals

Seven studies contained clear goals as to what should be accomplished for the safety of patients in a defined period of time by implementing the preventive bundle [25], [36], [47], [48], [50], [51], [53]. The aim of Cooley et al.’s initiative [47] was to reduce catheter-associated infection rates by a minimum of 50% in 12 months, which they achieved. The goal of reducing the CLABSI rate by 75% was not fully met by Fisher et al. [50], who attained 71%. Wilder et al. [48] obtained up to 92% real reduction of CLABSI rate from 2011 to 2014 versus a target rate of at least 50%, whereas Wirtschafter et al. [25] aimed for and reached a 25% reduction of the CLABSI rate. The initial incidence rate of CLABSI at the start of the initiative is a crucial factor for formulating a clear goal. At the start, catheter-associated incidence rates in these studies [25], [36], [47], [48], [50] ranged from 1.16 up to 4.32 CLABSI/1,000 PICC utilization days.

Clinical implementation of preventive bundles

The studies took different approaches to implementing the preventive bundle. In most studies, a higher-ranking, responsible multidisciplinary team [1], [3], [5], [6], [8], [10], [11], [16], [17], [18], [20], [21], [22], [23], [25] of up to 20 members [26] effected the implementation. Ting et al. [42] and Kilbride et al. [53] preferred implementing preventive measures in manageable “plan-do-check-act” cycles [31]. McMullan et al. [40] describe a structured training program according to the SCORPIO method [32] for implementing the preventive bundle. SCORPIO requires knowledge transfer and training of practical skills; thus, tutors explain and demonstrate the precise procedure to small groups in a multistep training environment (e.g., CVC insertion, dressing change, IV system change).

Feedback of surveillance findings and compliance rates to treatment team

Periodic feedback of current CLABSI rates to the treatment team is essential to illustrate the benefits of preventive measures or the initial extent of the problem. Many studies implemented this feedback [25], [26], [27], [29], [30], [33], [40], [44], [48], [49], [50]. McMullan et al. [40] describe a monthly feedback of CLABSI rates to the senior physician, a quarterly feedback to team members during the training program and a 6-month formal findings report on utilization rates and CLABSI rates. According to Bizzarro et al. [26] and Dumpa et al. [30], reports on interim findings and amount of days without CLABSI were displayed in the staff break room. According to Curry et al. [27], there was positive feedback after 100 CLABSI-free days and staff members were particularly praised (pizza party). Those studies reviewing the staff-member compliance with the preventive bundles kept their staff informed about results by displaying them on notice boards [33], [44] or by distributing a newsletter [48]. Shepherd et al. [29] report that the findings of compliance checks were made accessible in the hospital’s intranet.

Hand hygiene

Nearly all preventive bundles focussed on hand hygiene [24], [25], [26], [27], [29], [30], [33], [34], [36], [37], [38], [40], [42], [43], [44], [45], [46], [47], [48], [49], [50], [51], [52], [53]. Many preventive bundles [24], [25], [29], [33], [36], [42], [47], [48], [50], [51], [53] contained detailed instructions for hand hygiene. Some studies required the use of new disposable gloves in addition to hand disinfection upon each contact with an infusion system [24]. The compliance with hand hygiene was checked explicitly in 6 studies [33], [42], [43], [47], [49], [53]. Kime et al. [33] monitored hand hygiene compliance continuously. A survey among the medical staff showed that 85% of the staff members were not convinced of the specific benefit of intensified hand hygiene for preventing CLABSI [33]. The implementation of special hand hygiene training modules is mentioned in 10 studies [26], [30], [33], [34], [36], [37], [38], [44], [46], [49]. According to some American studies, e.g., Cooley et al. [47], hand washing with an antiseptic soap containing 2% chlorhexidine gluconate (CHG) was performed instead of disinfection of hands with alcohol.

Critical indication and limitation of indwelling

Some studies discussed a critical indication for inserting PICCs [37], [40]. In order to reduce the duration of indwelling, 8 studies [24], [25], [26], [28], [33], [38], [49], [50] defined criteria for PICC removal as early as possible. The catheter was removed in 6 studies as soon as enteral nutrition was 120 ml/kg/d [24], [25], [33], [38], [49], [50], and Bowen et al. [49] defined an enteral nutrition of 120–140 ml/kg for catheter removal.
in very immature preterm infants, above all in preterms with <1000 g birth weight during the first two weeks of life [1]. Ten out of 27 studies [28], [30], [33], [34], [38], [41], [45], [46], [49], [53] do not give precise information on choice of skin antiseptic. However, the preventive bundles of most studies explicitly specify skin antiseptics before insertion of CVC [25], [27], [29], [36], [40], [42], [44], [47], [50], [52] and recommend certain antiseptics in detail. Two studies report skin antiseptics with chlorhexidine (CHG) before inserting PICCs [25], [27], [36], [40], [47], [50]. Exposure time was said to be 30 sec to 3 minutes, with a longer exposure time when inserting a central line into the femoral vein [29], [36]. CHG concentration in these studies was between 0.015% and 3.15% [25], [29], [36], [40], [42], [44], [47], [48], [52], and the isopropanol concentration was between 4% for combined preparations and 70% [26], [29], [36], [42], [44], [47], [52]. In 6 studies [29], [36], [42], [44], [47], [52], skin antiseptics was effected by CHG 2%/isopropanol 70%. Five studies used povidone-iodine [25], [29], [36], [47], [50], Fisher et al. [50] and Piazza et al. [36] allowed skin antiseptics with isopropanol without CHG.

At dressing changes, catheter insertion points were disinfected with CHG in 6 studies [24], [27], [35], [43], [48], [51]. Two studies [42], [44] used CHG/isopropanol, 4 studies povidone-iodine [24], [26], [48], [51], and 1 study used isopropanol 70% instead of povidone-iodine [26]. Some studies had restrictions on antiseptic use, depending on birth weight, gestational and chronological age [27], [29], [36], [43], [44], [47]. According to Piazza et al. [36] and Shepherd et al. [29], 70% isopropanol or povidone-iodine was used in premature infants with a chronological age of less than 2 months, while CHG 2%/isopropanol 70% were used when the chronological age was ≥2 months. Cooley et al. [47] state CHG 2%/isopropanol 70% as antiseptic for neonates of ≥28 weeks (GA) and chronological age of ≥10 days, and povidone-iodine for younger neonates. Curry et al. [27] allowed CHG 2%/isopropanol 70% when birth weight was higher than 1,000 g and chronological (postnatal) age was at least 2 weeks. Chandonnet et al. [43] and Neill et al. [44] set the limit for using CHG 2%/isopropanol 70% at a minimum of 28 weeks of pregnancy. Ting et al. [42] stipulated swabbing the antiseptic with sterile saline solution at the end of exposure time in premature infants of BW <1,000 g.

**Maximum barrier precautions when inserting central lines**

The preventive bundles of most studies [25], [27], [29], [34], [35], [36], [37], [38], [40], [42], [43], [45], [47], [49], [50], [51], [52] require protective clothing (sterile gloves, surgical face mask, sterile coat, headgear) and extensive surgical draping of patient. Additionally, Piazza et al. [36], Fisher et al. [50], Kaplan et al. [51] and Wirtschafter et al. [25] recommend surgical face masks for staff assisting within a 1.5 m range. Headgear is not mentioned in all studies [42] and 10 studies do not give detailed information on preventive measures [24], [26], [28], [30], [33], [41], [44], [46], [48], [53].

**Empowerment of staff**

The assisting staff in 5 studies were entitled to stop catheter insertion when there was evidence of a failure to comply with preventive standards, which could make the insertion procedure not aseptic [24], [25], [42], [50], [51]. This medical staff followed a checklist for the decision to intervene [33], [42].

**Reviewing compliance, checklists, daily goals**

The benefit of preventive bundles can only be assessed realistically by checking the compliance with its preventive measures. 20 studies (74%) performed a compliance check [24], [25], [26], [29], [30], [33], [35], [36], [40], [42], [43], [44], [45], [46], [47], [48], [50], [51], [52], [53]. However, methods of monitoring and feedback varied widely. Specific inspection of hand hygiene was most frequent [25], [29], [33], [36], [40], [42], [43], [44], [47], [49], [53]. As part of the intervention, most studies [25], [29], [30], [33], [34], [35], [36], [37], [40], [42], [44], [45], [46], [50], [52] have checklists for catheter insertion and maintenance. Shepherd et al. [29] evaluated the compliance with preventive measures for inserting and maintaining catheters through independent monitoring according to checklists. After one year, the compliance with the preventive protocol for insertion and maintenance of catheters was constantly above 90%. Kaplan et al. [51] described a monthly check of compliance with each measure of the preventive bundle; compliance was over 90% in 24 NICUs, but there were also centers with lower compliance. 15 studies [24], [25], [26], [29], [33], [35], [36], [37], [38], [40], [43], [49], [50], [51], [52] used “daily goal sheets”. These are standardized forms to check and discuss critical control points during daily rounds, above all the question of whether the CVC must remain in situ or can be removed.

**Dressing changes**

Dressing changes are another keystone in preventing CLABSI. Dressing changes can be effected under extended barrier precautions [24], [25], [26], [29], [35], [36] or aseptically [27], [41], [52]. Holzmann-Pazgal et al. [35] describe extended barrier precautions for dressing changes; in addition to hand disinfection, the staff wore headgear, surgical face masks, sterile coats and sterile gloves. This was similar to Piazza et al. [36]. In some studies [26], [36], [41], [43], [44], [48], two persons were required for changing dressings.

In addition to these differences in daily practice, the studies showed no uniform dressing change interval. In 9 studies [26], [28], [33], [40], [44], [46], [47], [49], [52], the semipermeable transparent film dressing of PICC was
changed only when the dressing was contaminated, no longer intact or tending to detach. Curry et al. [27] implemented a weekly change of Broviac line dressing, including CHG-releasing sponges and a change of PICC dressings every 2 weeks. Not all protocols reported intervals for dressing changes [24]. Curry et al. [27] used CHG-releasing sponges to cover PICC insertion points in infants of at least 28 weeks gestational age and at least 10 days of chronological age. In individual patients with skin irritation, the CHG-releasing sponges were replaced by a silver-alginate dressing. The latter was used by Neill et al. [44] as well.

Change of infusion system

The preventive bundles of 13 studies give detailed instructions on changing procedures for infusion systems [25], [30], [33], [35], [36], [41], [42], [44], [47], [48], [51], [52], [53]. Only 2 protocols [41], [48] required 2 persons for a change. Eight studies [25], [30], [36], [41], [42], [44], [47], [53] recommended changing infusion systems at regular intervals. For example, Aly et al. [41] changed systems daily when lipid solutions, blood or blood products were administered. Short infusion systems were removed directly after administration. Neill et al. [44] changed the system every 96 hrs when administering crystalloid solutions without lipids. Ting et al. [42] and Kilbride et al. [53] changed infusion systems every 72 hrs. (in case of blood transfusion within 24 hrs). Dumpa et al. [30] and Cooley et al. [47] recommended changing the infusion system every 24 hrs.

Pre-assembled flushing syringes

As part of the preventive bundle, pre-assembled flushing syringes with sterile physiological saline solution were used in 3 multicenter studies [24], [25], [51] in order to eliminate the risk of contamination when filling the syringe manually.

Disinfection of catheter hub and other injection-connecting points

The preventive bundles of 19 studies [24], [25], [26], [27], [29], [35], [36], [40], [42], [44], [46], [49], [50], [51], [52] stressed the importance of disinfecting catheter-hub three-way valves and needle-free connection valves upon each direct manipulation (“scrub the hub”). However, the studies varied regarding antisepsics used and exact procedure. Many studies used CHG (mostly 2%) with or without isopropanol (70%) to disinfect hubs or injection points, and exposure time varied between 15 and 30 seconds. Seven studies did not state the exact drying time after disinfection [24], [27], [36], [40], [47], [50], [51]. Sannoh et al. [46] requested that the disinfectant should dry at least 30 seconds, Wirtschafter et al. demanded only 15 seconds [25].

Provision of necessary medical devices and products on a trolley

In 13 studies [25], [29], [30], [38], [42], [43], [46], [47], [48], [49], [50], [51], [52], a CVC trolley was present which provided all necessary medical products for catheter placement or dressing change. According to Sannoh et al. [46], all multi-bed rooms are equipped with such a trolley.

Specialized teams

A team of staff members with special skills/training was established in 10 studies [25], [27], [28], [29], [35], [36], [38], [43], [47], [48], in order to implement the preventive measures correctly. This team was responsible for PICC placement in 7 studies [25], [27], [28], [29], [36], [38], [47]. In some studies [25], [28], [35], [38], [43], [47], [48], this team was also responsible for maintaining care, e.g., change of system or dressing, or was explicitly responsible for supervision/monitoring and documenting PICC maintenance care [27], [28], [38], [47].

Endpoint CLABSI infection rates

Table 2 shows the effects of preventive bundles on CLABSI rates. A significant reduction of CLABSI rates was found in 17 [26], [27], [28], [29], [30], [34], [35], [37], [38], [40], [41], [42], [45], [46], [49], [52], [53] of the 27 studies – we included Kilbride et al. [53], although they only investigated blood stream infections by CoNS. The relative risk after intervention was stated to be 0.17 to 0.75. This equals a decreasing probability of CLABSI of 25% to 83%. Six studies give examples of significant effects on a high initial rate between 11.6 and 16.7 CLABSI/1,000 utilization days [33], [34], [38], [41], [45]. After intervening, the high initial rate drops to 0 to 5.2 CLABSI/1,000 utilization days. The findings of Kime et al. [33] show no statistical significance, while having a high clinical relevance with an initial rate of 15.6 CLABSI/1,000 utilization days and no CLABSI after intervention. Four additional studies [24], [43], [47], [48] exist which showed a non-significant decrease of CLABSI rate. Fisher et al. [50] report a reduction of CLABSI rate by 71% during a 10-month period. This was 19% in Piazza et al. [36] and 25% in Wirtschafter et al. [25]. Neill et al. [44] report that the number of events dropped by 92% in 5 years, from 6.08 to 0.45 per 1000 patient days. In addition, Figure 1 shows the results of a data meta-analysis from 8 studies which stated CLABSI incidences before and after intervention. Comparing groups before and after implementation of preventive bundles, the pooled relative risk (fixed effects, Mantel-Haenszel, Rothman-Boice) was at 0.58 (95% CI = 0.50–0.67) with moderate heterogeneity (I² 48.8%; 95% CI 0–74.5%). Funnel plots (Figure 2) of these studies and corresponding Egger’s tests for symmetry (−2.16; 95% CI −3.17 to −1.15; P=0.002) are indicating a possible publication bias in favor of a low
Discussion

By analyzing and meta-analyzing 27 studies, this survey proves the benefit of preventive bundles on the prevention of CLABSI in premature NICU patients. This should motivate NICU teams to define local preventive bundles according to the latest KRINKO recommendations and to implement these measures sustainably [55]. In this context, the NEO KISS module provides a well-established and standardized instrument for the prospective surveillance of CLABSI in premature infants, which allows NICU teams to present and provide feedback on the long-term effects of preventive bundles to the entire team.

The problem of safe and effective skin antisepsis in very immature preterm infants of BW<1,500 g is still unresolved [56], especially in the first two weeks of life when the skin is extremely vulnerable. Many studies use different concentrations of chlorhexidine gluconate (CHG) for skin antisepsis in premature infants, despite the fact that CHG may cause serious local skin irritations [57] and is
resorbed systemically [56], [58], [59], [60]. To date, it remains unclear which long-term consequences are caused by CHG exposure in premature infants. Based on an Orphan Drug approval of the European Medicines Agency (EMA), the KRINKO recommendations still name Octenidin 0.1% as the first-choice skin antiseptic. However, there is no commercially available ready-to-use product without 2% phenoxyethanol or 70% isopropanol. Even with Octenidin 0.1%, there is evidence of skin lesions in very immature preterm infants during the first 2 weeks of life [61]. Hence, the KRINKO currently recommends limiting exposed skin areas by using sterile drappings before skin antisepsis.

Preventive bundles to reduce CLABSI in NICUs are part of an NI prevention master plan for premature infants [13]; see also Bowen’s initiative for quality improvement [49]. Besides a preventive bundle for PICCs and PVCs, the author’s list of recommended preventive measures comprises additional information on structural-organisational aspects (e.g., patient-related medical products/stethoscopes, processing medical traps, administering mother’s...
milk and probiotics, kangarooing, visitor regulations and antibiotic stewardship in NICUs).

In Germany, there are additional measures in place such as weekly colonization screening to detect and stop the nosocomial transfer of antibiotic-resistant pathogens at an early stage [62], precautions for the aseptic reconstitution or preparation of medical products for parenteral use [63], [64], and concepts to decolonize premature infants colonized or infected with methicillin-resistant S. aureus [65].

**Limitations**

The investigated studies differed regarding the implementation of preventive bundles and definition of endpoints (see Table 2). The effect of different definitions can be made clear when we look at the consequences of the new 2008 definition of CLABSI caused by potential contaminants of blood culture, i.e., skin flora bacteria. According to the new CDC definition [54], coagulase-negative staphylococci (CoNS) must be detected in any case by means of two or more independently drawn blood cultures. Blood culture results reveal CoNS as the most frequent source of infection in premature NICU patients with late-onset sepsis diagnosed after the third day of life. Schulman et al. [52] describe a decrease of CoNS-caused CLABSI from 59% to 41% based only on the retrospective adaptation of CDC definitions after 2008. Accordingly, CoNS were not detected in two separately drawn blood cultures in 17% of CLABSI before 2008. Premature infants have a very low blood volume (100 ml/kg equalling 50 ml in an infant with a body weight of 500 g). Aerobic blood culture bottles are approved for this small blood volume, but fillings frequently fall short of the recommended minimum volume of 1 ml [66], [67], let alone drawing two such blood cultures of 1 ml each before starting an empirical antibiotic therapy. For the same reasons, it is not possible in neonatal intensive care to do routine parallel central and peripheral venous blood cultures in order to define the differential time to positivity. Relevant NEO KISS definitions, i.e., before the update in 2016, state “A single proof of coagulase-negative staphylococci does not necessarily rule out the diagnosis of clinical sepsis. Clinical sepsis may be diagnosed even with one proof of CoNS in blood culture when classified as contamination while not meeting CoNS sepsis criteria but meeting criteria for clinical sepsis.” A “microbiologically confirmed sepsis with CoNS as only pathogen” must be confirmed through at least one additional laboratory parameter and a minimum of two additional clinical criteria. To this extent the single proof of CoNS in the blood culture of a preterm patient with clinical sepsis may be assessed as contamination (“clinical sepsis”) or detection of a pathogen (“microbiologically verified sepsis with CNS as only pathogen”). Moreover, CLABSI are not established as certain catheter-originating infections [66]. Sepsis was considered to be a CLABSI when the patient had a central vascular access within 48 hrs before infection or at the beginning of the infection, and when there was no other primary focus of infection defined by imaging or clinical evaluation.

Semi-quantitative roll-plate culture of catheter tips [68] is not part of surveillance definitions for preterm infants, although significant growth (e.g., ≥15 CFU according to Maki’s method) points to the catheter as the probable source of the infection. CLABSI surveillance criteria are not decisive factors for clinical assessment of suspected late-onset infections.

The benefit of a preventive bundle can only be assessed realistically when we know how many times the components are definitely accomplished. Most study protocols of this survey (20 of 27; 74%) included a verification of compliance, but methods of near-patient monitoring and feedback differed widely. Supervision of compliance with hand hygiene seems highly useful [69]. This also applies to other crucial checkpoints, such as skin antisepsis and maximum barrier measures for PICC placement, disinfection of hubs, needle-free connective valves and other infection points before each manipulation, or procedural details for dressing and IV system changes. Many multicenter studies obliged participating centers to supervise and secure compliance with preventive measures. Well-trained hygiene specialist staff are highly suitable for checking the compliance through aimed auditing of NICUs, but such staff with sufficient working time are not available everywhere. Checklists and especially a strict provision requiring two licensed nurses for all critical manipulations like dressing changes or line changes are useful. In some studies, there were specialist teams to perform placement and maintenance of central lines [25], [27], [28], [29], [35], [36], [38], [43], [47], [48], whereas most German NICUs aim at personal responsibility in letting nurses and doctors perform necessary actions autonomously. Considerable efforts are necessary for the new introduction of preventive bundles concerning knowledge transfer courses and training skills, which must be taken into account, e.g., in terms of working time when planning the practical implementation of such measures [55]. The scientific examination of preventive bundles is not suited to showing the specific benefit of individual bundle components. Nevertheless, merging individual measures of proven benefit in term of reducing infection risks may result in a higher overall effect on CLABSI rates.

In conclusion, our evaluation impressively confirms the benefit of preventive bundles regarding the prevention of CVC-associated infections in premature NICU patients. The heads of German NICUs should examine local preventive strategies according to KRLKO recommendations. Preventive bundles should be defined together with all involved professional groups and sustainably implemented in daily clinical routine.
Abbreviations

- BW – birth weight
- CDC – Centers for Disease Control and Prevention, Atlanta, USA
- CLABSI – central line associated bloodstream infections
- CFU – colony forming units
- CHG – chlorhexidine gluconate
- CNS – coagulase-negative staphylococci
- CRBSI – catheter related bloodstream infection
- CVC – central venous catheter
- ELBW – extremely low birth weight (<1,000 g)
- GA – gestational age
- ICU – intensive care unit
- KRINKO – German Commission for Hospital Hygiene and Infection Prevention affiliated to the Robert Koch Institute, Berlin, Germany
- LOS – late-onset sepsis
- NI – nosocomial infection
- NICU – neonatal intensive care unit
- PICC – peripherally inserted central venous catheter
- PVC – peripheral venous indwelling cannula
- UAC – umbilical artery catheter
- UVC – umbilical vein catheter
- VLBW – very low birth weight (<1,500 g)

Notes

Competing interests

The authors declare that there are no conflicts of interest. Prof. Simon is coordinator of the working group on neonatal intensive care of the German Commission for Hospital Hygiene and Infection Prevention affiliated to the Robert Koch Institute in Berlin, Germany. Prof. Geffers is leader of the NEO-KISS surveillance module of the German National Reference Center for Surveillance of Nosocomial Infections, Institute for Hygiene and Environmental Medicine at the Charité in Berlin, Germany.

Acknowledgements

Our thanks go to all members of the working group on neonatal intensive care of the Commission for Hospital Hygiene and Infection Prevention, Dr. Jürgen Christoph, Prof. Dr. Christof Dame, Prof. Dr. Christian Gille, Prof. Dr. Christoph Härtel, Prof. Dr. Irene Krämer, Dr. Matthias Marschal, Prof. Dr. Andreas Müller, Prof. Dr. Mardjan Arvand and Vanda Marujo.
12. Geffers C, Schwab F, Gastmeier P. Nosokomiale Infektionen bei pädiatrischen Intensivpflegepatienten. Daten aus ITS-KISS. Hygiene & Medizin. 2009;34(9):336-342.

13. Empfehlung zur Prävention nosokomialer Infektionen bei neonatologischen Intensivpflegepatienten mit einem Geburtsgewicht unter 1500 g. Mitteilung der Kommission für Krankenhaushygiene und Infektionsprävention beim Robert Koch-Institut [Recommendation for the prevention of nosocomial infections in neonatal intensive care patients with a birth weight less than 1,500 g. Report by the Committee of Hospital Hygiene and Infection Prevention of the Robert Koch Institute]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2007 Oct;50(10):1265-303.

14. Prävention von Gefäßkatheter-assoziierten Infektionen bei Früh- und Neugeborenen: Empfehlung der Kommission für Krankenhaushygiene und Infektionsprävention (KRINKO) beim Robert Koch-Institut. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2018 May;51(5):608-626. DOI: 10.1007/s00103-018-2719-y

15. Härtel C, Simon A, Geffers C, Schaper A, Herting E, Göpel W; German Neonatal Network (GNN); Nosokomiale Infektionen bei Frühgeborenen: Umsetzung der KRINKO-Empfehlungen im Deutschen Frühgeborenenetzwerk. Monatschr Kinderheilkd. 2013;161(1):27-33. DOI: 10.1007/s00112-012-2845-8

16. Bizzarro MJ, Shabanova V, Baltimore RS, Dembry LM, Ehrenkranz RA, Gallagher PG. Neonatal sepsis 2004-2013: the rise and fall of coagulase-negative staphylococci. J Pediatr. 2015 May;166(5):1193-9. DOI: 10.1016/j.jpeds.2015.02.009

17. Helder O, Kornelisse R, van der Starre C, Tibboel C, Looman C, Wijnen R, Poley M, Ista E. Implementation of a children's hospital-wide central venous catheter insertion and maintenance bundle. BMC Health Serv Res. 2013 Oct 14;13:417. DOI: 10.1186/1472-6963-13-417

18. Helder O, van den Hoogen A, de Boer C, van Goudeover J, Verboon-Macieklo M, Kornelisse R. Effectiveness of non-pharmacological interventions for the prevention of bloodstream infections in infants admitted to a neonatal intensive care unit: A systematic review. Int J Nurs Stud. 2013 Jun;50(8):819-31. DOI: 10.1016/j.ijnurstu.2012.05.009

19. Stevens TP, Schulman J. Evidence-based approach to preventing central line-associated bloodstream infection in the NICU. Acta Paediatr. 2012 Apr;101(464):11-6. DOI: 10.1111/j.1651-2227.2011.02547.x

20. Powers RJ, Wirthschafter DW. Decreasing central line associated bloodstream infection in neonatal intensive care. Clin Perinatol. 2010 Mar;37(1):247-72. DOI: 10.1016/j.clp.2010.01.014

21. Lachman P, Yuen S. Using care bundles to prevent infection in neonatal and paediatric ICUs. Curr Opin Infect Dis. 2009 Jun;22(3):224-8. DOI: 10.1097/QCO.0b013e3282397b68

22. Smulders CA, van Gestel JP, Bos AP. Are central line bundles and ventilator bundle efforts in critically ill neonates and children? Intensive Care Med. 2013 Aug;39(8):1352-8. DOI: 10.1007/s00134-013-2927-7

23. Fisher D, Cochran KM, Provost LP, Patterson J, Bristol T, Metzger K, Smith B, Testoni D, McCaffrey MJ. Reducing central line-associated bloodstream infections in North Carolina NICUs. Pediatrics. 2013 Dec;132(6):e1664-71. DOI: 10.1542/peds.2013-200

24. Health Research & Educational Trust; Perinatal Quality Collaborative of North Carolina (PQCC); Missouri Center for Patient Safety (MOPPS). Eliminating CLABSI, A National Patient Safety Imperative. A Progress Report on the National On theCUSP: Stop BSI Project, Neonatal Catheter Prevention. AHQR; 2012. Available from: https://www.ahrq.gov/professionals/quality-patient-safety/cusp/clabsi-neonatal/index.html

25. Wirtschafter DD, Pettit J, Kurtin P, Dalsey M, Chance K, Morrow HW, Seid M, Byczkowski TL, Huber TP, Milstein JM, Bowles SM, Fichera S, Kloman A. A statewide quality improvement collaborative to reduce neonatal central line-associated bloodstream infections. J Perinatol. 2010 Mar;30(3):170-81. DOI: 10.1093/jpeds/2009.172

26. Bizzarro MJ, Sabo B, Noonan M, Bonfiglio MP, Northup V, Diefenbach K; Central Venous Catheter Initiative Committee. A quality improvement initiative to reduce central line-associated bloodstream infections in a neonatal intensive care unit. Infect Control Hosp Epidemiol. 2010 Mar;31(3):241-8. DOI: 10.1086/650448

27. Curry S, Honeycutt M, Goins G, Gilliam C. Catheter-associated bloodstream infections in NICU: getting to zero. Neonatal Netw. 2009 May-Jun;28(3):151-5. DOI: 10.1891/0730-0832.28.3.151

28. Golombok SG, Rohan AJ, Parvez B, Salice AL, La Gamma EF. “Proactive” management of percutaneously inserted central catheters results in decreased incidence of infection in the ELBW population. J Perinatol. 2002 Apr-May;22(3):209-13. DOI: 10.1036/sjp.7210660

29. Shepherd EG, Kelly TJ, Vineal JA, Cunningham DJ, Keels E, Beauseau W, McClead RE Jr. Significant Reduction of Central-Line Associated Bloodstream Infections in a Network of Diverse Neonatal Nurseries. J Pediatr. 2015 Jul;167(1):41-6. DOI: 10.1016/j.jpeds.2015.03.046

30. Dumps V, Adler B, Allen D, Bowman D, Gram A, Ford P, Sannoh S. Reduction in Central Line-Associated Bloodstream Infections Rates After Implementations of Infection Control Measures at a Level 3 Neonatal Intensive Care Unit. Am J Med Qual. 2016 Mar-Apr;31(2):133-8. DOI: 10.1177/1062860614557637

31. Medina A, Serrat R, Pelte M, Brancamp T. Decreasing central line-associated bloodstream infections in the Non-ICU population. J Nurs Care Qual. 2014 Apr-Jun;29(2):133-40. DOI: 10.1097/NCQ.0000000000000034

32. Taylor JE, McDonald SJ, Tan K. Prevention of central venous catheter-related infection in the neonatal unit: a literature review. J Matern Fetal Neonatal Med. 2015 Jul;28(10):1224-30. DOI: 10.3109/14767058.2014.949663

33. Kime T, Mohsini K, Nwankwo MU, Turner B. Central line “attention” is their best prevention. Adv Neonatal Care. 2011 Aug;11(4):242-8. quiz 249-50. DOI: 10.1097/ANC.0b013e3182256680

34. Steiner M, Langgarter M, Cardona F, Waldhörf T, Schwindt J, Haiden N, Berger A. Significant Reduction of Catheter-associated Bloodstream Infections in Preterm Neonates After Implementation of a Care Bundle Focusing on Simulation Training of Central Line Insertion. Pediatr Infect Dis J. 2015 Jun;34(11):1193-6. DOI: 10.1097/INF.0000000000000841

35. Holzmann-Pazgal G, Kubanda A, Davis K, Khan AM, Brumley K, Denson SE. Utilizing a line maintenance team to reduce central-line-associated bloodstream infections in a neonatal intensive care unit. J Perinatol. 2016 Apr;32(4):281-6. DOI: 10.1038/jpeds.2011.91

36. Piazza AJ, Brozanski B, Provost L, Grover TR, Choo J, Smith JR, Mingrone T, Moran S, Morelli L, Zanietti I, Pallotto EK. SLUG Bug: Quality Improvement With Orchestrated Testing Leads to NICU CLABSI Reduction. Pediatrics. 2016 Jan;137(1):e20143642. DOI: 10.1542/peds.2014-3642

37. Salm F, Schwab F, Geffers C, Gastmeier P, Pieening B. The Implementation of an Evidence-Based Bundle for Bloodstream Infections in Neonatal Intensive Care Units in Germany: A Controlled Intervention Study to Improve Patient Safety, Infect Control Hosp Epidemiol. 2016 Jul;37(7):798-804. DOI: 10.1017/ice.2016.72
38. Zhou Q, Lee SK, Hu XJ, Jiang SY, Chen C, Wang CQ, Cao Y. Successful reduction in central line-associated bloodstream infections in a Chinese neonatal intensive care unit. Am J Infect Control. 2015 Mar;143(3):275-9. DOI: 10.1016/j.ajic.2014.12.001

39. Snyder GM, Young H, Varman M, Milstone AM, Harris AD, Munoz-Price S. Research Methods in Healthcare Epidemiology and Antimicrobial Stewardship-Observational Studies. Infect Control Hosp Epidemiol. 2016 Oct;37(10):1141-6. DOI: 10.1017/ice.2016.118

40. McManus R, Gordon A. Impact of a Central Line Infection Prevention Bundle in Newborn Infants. Infect Control Hosp Epidemiol. 2016 Sep;37(9):1029-36. DOI: 10.1017/ice.2016.127

41. Aly H, Herson V, Duncan A, Herr J, Bender J, Patel K, El-Mohandes AA. Is bloodstream infection preventable among premature infants? A tale of two cities. Pediatrics. 2005 Jun;115(6):1513-8.

42. Ting JY, Goh VS, Osovich H. Reduction of central line-associated bloodstream infection rates in a neonatal intensive care unit after implementation of a multidisciplinary evidence-based quality improvement collaborative: A four-year surveillance. Can J Infect Dis Med Microbiol. 2013 Winter;24(4):185-90. DOI: 10.1155/2013/781690

43. Chandonnet C, Kahlon PS, Rachh P, Degrizia M, Dewitt EC, Flaherty KA, Spigel N, Packard S, Casey D, Rachwil C, Agrawal PB. Health care failure mode and effect analysis to reduce NICU line-associated bloodstream infections. Pediatrics. 2013 Jun;131(6):e1961-9. DOI: 10.1542/peds.2012-3293

44. Neill S, Haithcock S, Smith PB, Goldberg R, Bidegain M, Tanaka C, Chandonnet C, Kahlon PS, Rachh P, Degrizia M, Dewitt EC, Flaherty KA, Spigel N, Packard S, Casey D, Rachwil C, Agrawal PB. Health care failure mode and effect analysis to reduce NICU line-associated bloodstream infections. Pediatrics. 2013 Jun;131(6):e1961-9. DOI: 10.1542/peds.2012-3293

45. Lashkari HP, Chow P, Godambe S. Aqueous 2% chlorhexidine-induced chemical burns in an extremely premature infant. Arch Dis Child Fetal Neonatal Ed. 2012 Jan;97(1):F64. DOI: 10.1136/adc.2011.215145

46. Ponnusamy V, Venkatesh V, Clarke P. Skin antiseptic in the neonate: what should we use? Curr Opin Infect Dis. 2014 Jun;27(3):244-50. DOI: 10.1097/QCO.0000000000000664

47. Lashkari HP, Chow P, Godambe S. Aqueous 2% chlorhexidine-induced chemical burns in an extremely premature infant. Arch Dis Child Fetal Neonatal Ed. 2012 Jan;97(1):F64. DOI: 10.1136/adc.2011.215145

48. Garland JS, Uging MR, Peterside IE, Rentz A, Harris MC. Pilot trial to compare tolerance of chlorhexidine gluconate to povidone-iodine antiseptic for central venous catheter placement in neonates. J Perinatol. 2009 Dec;29(12):808-13. DOI: 10.1038/jp.2009.161

49. Aggett PJ, Cooper LV, Ellis SH, McInish J. Percutaneous absorption of chlorhexidine in neonatal cord care. Arch Dis Child. 1981 Nov;56(11):878-80. DOI: 10.1136/adc.56.11.878

50. Chapman AK, Aucott SW, Gilmore MM, Advani S, Clarke W, Milstone AM. Absorption and tolerability of aqueous chlorhexidine gluconate used for skin antiseptic prior to catheter insertion in preterm neonates. J Perinatol. 2015 Oct;35(10):788-91. DOI: 10.1038/jp.2013.61

51. Kaplan HC, Lannon C, Walsh MC, Donovan EF; Ohio Perinatal Quality Collaborative. Ohio statewide quality-improvement collaborative to reduce late-onset sepsis in preterm infants. Pediatrics. 2011 Mar;127(3):427-35. DOI: 10.1542/peds.2010-2141

52. Schulman J, Stricof R, Stevens TP, Horgan M, Gase K, Holzman IR, Koppel RI, Nafdy S, Gibbs K, Angert R, Simmonds A, Furdon SA, Saiman L; New York State Regional Perinatal Care Centers. Statewide NICU central-line-associated bloodstream infection rates decline after bundles and checklists. Pediatrics. 2011 Mar;127(3):436-44. DOI: 10.1542/peds.2010-2873

53. Klibride HW, Wintersaffer DD, Powers RJ, Sheehan MB. Implementation of evidence-based potentially better practices to decrease nosocomial infections. Pediatrics. 2003 Apr;111(4 Pt 2):e519-33.

54. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008 Jun;36(5):309-32. DOI: 10.1016/j.ajic.2008.03.002

55. Kommission für Krankenhaushygiene und Infektionsprävention beim Robert Koch-Institut. Prävention von Infektionen, die von Gefäßkathetern ausgehen: Hinweise zur Implementierung Informativer Anhang 2 zur Empfehlung für Krankenhaushygiene und Infektionsprävention (KRINKO) beim Robert Koch-Institut. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 2017;60(2):231-44.

56. Biermann CD, Kribs A, Roth B, Tantcheva-Poor I. Use and implementation of a central line dressing change bundle in neonates. Am J Infect Control. 2016 Apr;44(4):485-7. DOI: 10.1016/j.ajic.2016.04.002

57. Kommission für Krankenhaushygiene und Infektionsprävention beim Robert Koch-Institut. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 2017;60(2):231-44.

58. Schulman J, Stricof R, Stevens TP, Horgan M, Gase K, Holzman IR, Koppel RI, Nafdy S, Gibbs K, Angert R, Simmonds A, Furdon SA, Saiman L; New York State Regional Perinatal Care Centers. Statewide NICU central-line-associated bloodstream infection rates decline after bundles and checklists. Pediatrics. 2011 Mar;127(3):436-44. DOI: 10.1542/peds.2010-2873

59. Klibride HW, Wintersaffer DD, Powers RJ, Sheehan MB. Implementation of evidence-based potentially better practices to decrease nosocomial infections. Pediatrics. 2003 Apr;111(4 Pt 2):e519-33.

60. Flaherty KA, Spigel N, Packard S, Casey D, Rachwil C, Agrawal PB. Health care failure mode and effect analysis to reduce NICU line-associated bloodstream infections. Pediatrics. 2013 Jun;131(6):e1961-9. DOI: 10.1542/peds.2012-3293

61. Kilbride HW, Wintersaffer DD, Powers RJ, Sheehan MB. Implementation of evidence-based potentially better practices to decrease nosocomial infections. Pediatrics. 2003 Apr;111(4 Pt 2):e519-33.

62. Flaherty KA, Spigel N, Packard S, Casey D, Rachwil C, Agrawal PB. Health care failure mode and effect analysis to reduce NICU line-associated bloodstream infections. Pediatrics. 2013 Jun;131(6):e1961-9. DOI: 10.1542/peds.2012-3293

63. Kilbride HW, Wintersaffer DD, Powers RJ, Sheehan MB. Implementation of evidence-based potentially better practices to decrease nosocomial infections. Pediatrics. 2003 Apr;111(4 Pt 2):e519-33.

64. Flaherty KA, Spigel N, Packard S, Casey D, Rachwil C, Agrawal PB. Health care failure mode and effect analysis to reduce NICU line-associated bloodstream infections. Pediatrics. 2013 Jun;131(6):e1961-9. DOI: 10.1542/peds.2012-3293

65. Kilbride HW, Wintersaffer DD, Powers RJ, Sheehan MB. Implementation of evidence-based potentially better practices to decrease nosocomial infections. Pediatrics. 2003 Apr;111(4 Pt 2):e519-33.
63. Arbeitsgruppe KRINKO-BfArM-RKI. Bericht der Arbeitsgruppe KRINKO-BfArM-RKI: Zu spezifischen Fragen bezüglich Rekonstitution, Zubereitung und Applikation von Arzneimitteln und Infusionslösungen sowie zur Hautantiseptik. Epidemiol Bulletin des Robert Koch-Instituts. 2016 May 23;20:173-8.

64. Council of Europe, Committee of Ministers. Resolution CM/Res(2016)2 on good reconstitution practices in health care establishments for medicinal products for parenteral use. 2016 Jun 1. Available from: https://www.edqm.eu/sites/default/files/resolution_cm_res_2016_2_good_reconstitution_practices_in_health_care_establishments_for_medicinal_products_for_parenteral_use_.pdf

65. Nelson MU, Bizzarro MJ, Dembry LM, Baltimore RS, Gallagher PG. One size does not fit all: why universal decolonization strategies to prevent methicillin-resistant Staphylococcus aureus colonization and infection in adult intensive care units may be inappropriate for neonatal intensive care units. J Perinatol. 2014 Sep;34(9):653-5. DOI: 10.1038/jp.2014.125

66. Kommission für Krankenhaushygiene und Infektionsprävention beim Robert Koch-Institut. Prävention von Infektionen, die von Gefäßkathetern ausgehen: Hinweise zur Blutkulturdiagnostik - Informativer Anhang 1 zur Empfehlung der Kommission für Krankenhaushygiene und Infektionsprävention (KRINKO) beim Robert Koch-Institut. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 2017;60(2):216–30.

67. Dien Bard J, McElvania Te Kippe E. Diagnosis of Bloodstream Infections in Children. J Clin Microbiol. 2016 Jun;54(6):1418-24. DOI: 10.1128/JCM.02919-15

68. Maki DG, Weise CE, Sarafin HW. A semiquantitative culture method for identifying intravenous-catheter-related infection. N Engl J Med. 1977 Jun 9;296(23):1305-9.

69. Kommission für Krankenhaushygiene und Infektionsprävention beim Robert Koch Institut. Händehygiene in Einrichtungen des Gesundheitswesens - Empfehlung der Kommission für Krankenhaushygiene und Infektionsprävention (KRINKO) beim Robert Koch-Institut (Rki). Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 2016;59(9):1189–220.

Corresponding author:
Prof. Dr. med. Arne Simon
University Hospital of the Saarland, Children’s Hospital, Pediatric Oncology and Hematology, Kirrbergerstr. UKS-building 9, 66421 Homburg, Germany, Phone: +49 6841/1628399
Arne.Simon@uks.eu

Please cite as Schmid S, Geffers C, Wagenpfeil G, Simon A. Preventive bundles to reduce catheter-associated bloodstream infections in neonatal intensive care. GMS Hyg Infect Control. 2018;13:Doc10. DOI: 10.3205/dgkh000316, URN: urn:nbn:de:0183-dgkh0003169

This article is freely available from http://www.egms.de/en/journals/dgkh/2018-13/dgkh000316.shtml

Published: 2018-11-16

Copyright ©2018 Schmid et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.